Skip to search formSkip to main contentSkip to account menu

LY-2157299

Known as: LY 2157299, LY2157299 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PyrazolesQuinolines

Narrower (1)

galunisertib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
TGF-b inhibition enhances chemotherapy action against triple-negative breast cancer
After an initial response to chemotherapy, many patients with triple-negative breast cancer (TNBC) have recurrence of drug… 
2018
2018
Sorafenib suppresses TGF‐&bgr; responses by inducing caveolae/lipid raft‐mediated internalization/degradation of cell‐surface type II TGF‐&bgr; receptors: Implications in development of effective…
2015
2015
When good transforming growth factor‐β turns bad in hepatocellular carcinoma: Axl takes the stage
H epatocellular carcinoma (HCC) is one of the most frequent and lethal cancers worldwide, with limited treatment options when the… 
2015
2015
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.
Transforming growth factor-β (TGF-β) signaling is associated with tumor progression and vascularization in malignant glioma. In… 
2013
2013
Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma…
4118 Background: TGF-s signaling is associated with HCC progression in moderate to poorly differentiated tumors overexpressing… 
2013
2013
Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in…
2563 Background: Based on animal studies, the combination of a TGF-β inhibitor and gemcitabine is expected to enhance antitumor… 
2013
2013
Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in…
2061 Background: Based on preclinical data suggesting an additive antitumor effect of a TGF-s inhibitor and lomustine, a phase II… 
2012
2012
The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.
2042 Background: Activated TGF-b signaling has been associated with poor survival in several tumors, including glioma. TGF-b… 
2011
2011
First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
3011 Background: Activated TGF-b signaling has been associated with poor survival in several tumors, including glioma… 
2005
2005
Targeting the TGF-β RI kinase with LY2157299: A PK/PD-driven drug discovery and clinical development program
SY13-2 Transforming growth factor-β (TGF-β) is a cytokine with diverse biological activities. TGF-β’s role as a tumor suppressor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)